SOAT1 and enterocolitis: In keeping with our previous report that the JAK1/2 inhibitor ruxolitinib effectively inhibited enterocolitis in a patient with STAT3 gain of function mutation,40 our findings strengthen the argument that a subgroup of IBD patients may benefit from a tight control of the JAK/STAT pathway to inhibit intestinal inflammation.